Pharmanutra Forecast, price target & analysts
Why the stock moved Beta
Pharmanutra Target price 2026 - Analyst rating & recommendation
Pharmanutra Classifications & Recommendation
Pharmanutra Price Target
| Target Price | €94.86 |
| Price | €73.30 |
| Potential |
29.41%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Pharmanutra 2027 .
The average Pharmanutra target price is €94.86.
This is
29.41%
register free of charge
€102.90
40.38%
register free of charge
€92.92
26.77%
register free of charge
|
|
| A rating was issued by 7 analysts: 6 Analysts recommend Pharmanutra to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Pharmanutra stock has an average upside potential 2027 of
29.41%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million € | 131.69 | 156.20 |
| 14.02% | 18.61% | |
| EBITDA Margin | 25.61% | 26.08% |
| 4.26% | 1.82% | |
| Net Margin | 15.19% | 15.97% |
| 5.61% | 5.15% |
4 Analysts have issued a sales forecast Pharmanutra 2026 . The average Pharmanutra sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Pharmanutra EBITDA forecast 2026. The average Pharmanutra EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 Pharmanutra Analysts have issued a net profit forecast 2026. The average Pharmanutra net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share € | 2.09 | 2.60 |
| 20.81% | 24.40% | |
| P/E | 29.66 | |
| EV/Sales | 4.51 |
4 Analysts have issued a Pharmanutra forecast for earnings per share. The average Pharmanutra EPS is
This results in the following potential growth metrics and future valuations:
Current Pharmanutra Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BERENBERG |
Locked
➜
Locked
|
Locked | Jun 15 2026 |
| TP ICAP |
Locked
➜
Locked
|
Locked | May 10 2026 |
| BERENBERG |
Locked
➜
Locked
|
Locked | Mar 02 2026 |
| MIDCAP PARTNERS |
Locked
➜
Locked
|
Locked | Feb 02 2026 |
| MIDCAP PARTNERS |
Locked
➜
Locked
|
Locked | Jan 13 2026 |
| MIDCAP PARTNERS |
Locked
➜
Locked
|
Locked | Nov 21 2025 |
| BERENBERG |
Locked
➜
Locked
|
Locked | Nov 11 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
BERENBERG:
Locked
➜
Locked
|
Jun 15 2026 |
|
Locked
TP ICAP:
Locked
➜
Locked
|
May 10 2026 |
|
Locked
BERENBERG:
Locked
➜
Locked
|
Mar 02 2026 |
|
Locked
MIDCAP PARTNERS:
Locked
➜
Locked
|
Feb 02 2026 |
|
Locked
MIDCAP PARTNERS:
Locked
➜
Locked
|
Jan 13 2026 |
|
Locked
MIDCAP PARTNERS:
Locked
➜
Locked
|
Nov 21 2025 |
|
Locked
BERENBERG:
Locked
➜
Locked
|
Nov 11 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
